Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.   24 October 2024
Careers
Keo McKenzie re-joins firm’s Washington, DC office, bringing over a decade of experience in AI, healthcare, and technology law.   24 October 2024
Americas
10x Genomics senior director of IP and litigation shares her team's tasks, how she’s handling UPC litigation, and why sometimes she wants a ‘gut answer’ from externals, finds Marisa Woutersen.   22 October 2024
Americas
Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.   22 October 2024
Americas
In-house pharma and biotech lawyers are taking on broader roles, from handling regulatory issues to corporate strategy—and outside counsel can help, finds Marisa Woutersen.   22 October 2024
Asia
Association’s annual event is held in China for the first time I Vice premier of China, Zhang Guoqing, delivers Xi's message of IP 'cooperation' | More than 2,300 delegates treated to cultural shows in Hangzhou that were premiered before the G20 | LSIPR sister title WIPR among more than 80 exhibitors at the city’s expo centre.   22 October 2024
Americas
At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.   17 October 2024
Careers
Former patent examiner and federal clerk brings expertise in cutting-edge technologies to the US firm.   17 October 2024
Americas
As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.   17 October 2024
Americas
UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.   16 October 2024